Answers are grounded in this paper and cite their sources.
Less than half of community pharmacies in the United States stock buprenorphine products indicated for the treatment of opioid use disorder. This lack of access to buprenorphine in community pharmacies is a significant barrier to care. To address this issue, this protocol outlines a comprehensive approach to develop a practice guideline aimed at improving access to safe and effective opioid use disorder treatment in community pharmacies.
No takes yet. Share an insight, caveat, or question.
Varisco et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: